"Anthracyclines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Organic compounds that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.
| Descriptor ID |
D018943
|
| MeSH Number(s) |
D02.455.426.559.847.562.050 D04.615.562.050 D09.408.051.059
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Anthracyclines".
Below are MeSH descriptors whose meaning is more specific than "Anthracyclines".
This graph shows the total number of publications written about "Anthracyclines" by people in this website by year, and whether "Anthracyclines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 2 | 2 |
| 2007 | 1 | 1 | 2 |
| 2008 | 1 | 0 | 1 |
| 2010 | 1 | 1 | 2 |
| 2014 | 3 | 0 | 3 |
| 2015 | 1 | 0 | 1 |
| 2016 | 2 | 0 | 2 |
| 2017 | 1 | 2 | 3 |
| 2018 | 1 | 1 | 2 |
| 2020 | 2 | 1 | 3 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 2 | 2 |
| 2024 | 0 | 1 | 1 |
| 2025 | 1 | 4 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Anthracyclines" by people in Profiles.
-
Neoadjuvant HER2-targeted regimens with or without anthracyclines for HER2-positive inflammatory breast cancer: a multicenter retrospective study. Breast Cancer Res Treat. 2025 Nov; 214(1):69-77.
-
Predicting the 10-year risk of cardiomyopathy in long-term survivors of childhood cancer. Ann Oncol. 2025 Oct; 36(10):1203-1211.
-
TTN and BAG3 in Cancer Therapy-Related Cardiomyopathy Among Long-Term Survivors of Childhood Cancer. JAMA Netw Open. 2025 06 02; 8(6):e2515793.
-
Immunomodulatory gene networks predict treatment response and survival to de-escalated, anthracycline-free neoadjuvant chemotherapy in triple-negative breast cancer in the WSG-ADAPT-TN trial. Mol Cancer. 2025 Mar 26; 24(1):96.
-
Cardiovascular Toxicity in Patients Treated for Childhood Cancer: A Scientific Statement From the American Heart Association. Circulation. 2025 Apr 15; 151(15):e926-e943.
-
Intensification of upfront chemotherapy for patients with myeloid blast phase CML: a single center experience. Ann Hematol. 2024 Dec; 103(12):5395-5403.
-
Low-grade fibromyxoid sarcoma and sclerosing epithelioid fibrosarcoma, outcome of advanced disease: retrospective study from the Ultra-Rare Sarcoma Working Group. ESMO Open. 2024 Sep; 9(9):103689.
-
Risk of anthracycline-induced cardiac dysfunction in adolescent and young adult (AYA) cancer survivors: role of genetic susceptibility loci. Pharmacogenomics J. 2024 Jun 29; 24(4):21.
-
Obesity Predisposes Anthracycline-Treated Survivors of Childhood and Adolescent Cancers to Subclinical Cardiac Dysfunction. Pediatr Cardiol. 2025 Feb; 46(2):362-371.
-
Guidelines for Standardization of Pediatric Anthracycline Cardiomyopathy Echocardiogram Surveillance-A Call for Harmonization in the Field to Enhance Research in the Cancer Survivor Population. Pediatr Cardiol. 2024 02; 45(2):452-453.